BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28

• 

  Drug Development

  Clinical Catch-Up: February 22-26

  It was another busy week for clinical trial news. Here’s a look.

  February 26, 2021

   · 

  7 min read

   · 

  Mark Terry
• 

  FDA

  FDA Action Alert: Athenex, Blueprint, CorMedix and More

  The end of February and beginning of March is a busy time for the U.S. Food and Drug Administration, with a number of PDUFA dates on the calendar.

  February 26, 2021

   · 

  6 min read

   · 

  Mark Terry
• 

  Drug Development

  AstraZeneca, Amgen Breathing Easier with Optimistic Phase III Asthma Drug Results

  After announcing a successful primary endpoint in November, AstraZeneca and Amgen presented the full data on their severe asthma antibody candidate on Friday.

  February 26, 2021

   · 

  3 min read

   · 

  Kate Goodwin
• 

  Biotech Beach

  Artiva Raises $120 Million to Advance Pipeline of Allogeneic NK Cell Therapies

  Funds will be used to support the development of its lead asset, AB-101, an ADCC enhancer NK-cell therapy for use in combination with monoclonal antibodies or innate-cell engagers.

  February 26, 2021

   · 

  2 min read

   · 

  Alex Keown
• 

  Drug Development

  Merck’s OncoImmune COVID-19 Therapeutic Stuck at Starting Gate Pending Further Data

  On Thursday, the company said the U.S. Food and Drug Administration wants to see additional data beyond the Phase III study announced last year.

  February 26, 2021

   · 

  2 min read

   · 

  Alex Keown
• Perceptive Advisors’ ARYA Sciences Acquisition IV Raises $130 Million in IPO

  Perceptive Advisors’ fourth healthcare blank check company ARYA Sciences Acquisition IV announced it has raised up to $130 million through the offering of 13 million shares at $10.

  February 26, 2021

   · 

  2 min read

   · 

  Brandon May
• 

  FDA

  FDA Approves Third Sarepta Treatment For Duchenne Muscular Dystrophy

  The U.S. FDA approved Sarepta Therapeutics’ Amondys 45 (casimersen) for patients with Duchenne muscular dystrophy (DMD) who have a confirmed mutation amenable to exon 45 skipping.

  February 26, 2021

   · 

  3 min read

   · 

  Mark Terry
• 

  Deals

  Roivant Dives Deeper into AI with $450 Million Buy of Silicon Therapeutics

  The Silicon Therapeutics acquisition is designed to complement Roivant’s targeted protein degradation platform.

  February 26, 2021

   · 

  3 min read

   · 

  Mark Terry
• 

  Business

  Field Trip Health’s New Psilocybin Research Facility Probes the Secrets of Shrooms

  The world’s first legal research and cultivation facility dedicated exclusively to psilocybin-producing mushrooms (called shrooms or magic mushrooms) and other plant-based psychedelics recently opened in Jamaica.

  February 26, 2021

   · 

  4 min read

   · 

  Gail Dutton
• How Demand for Renovascular Hypertension Treatment Growth Spurred by Increasing Prevalence of Kidney Disorders, Opines Fact.MR

  Fact.MR, a global research & consulting firm, in their latest edition of the report, projected that the renovascular hypertension treatment market is anticipated to see moderate growth pace in 2021 and beyond.

  February 26, 2021

   · 

  4 min read